Korro Bio, Inc. (NASDAQ:KRRO) Shares Acquired by Brown Brothers Harriman & Co.

Brown Brothers Harriman & Co. boosted its position in shares of Korro Bio, Inc. (NASDAQ:KRRO) by 251.0% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,854 shares of the company’s stock after buying an additional 2,041 shares during the quarter. Brown Brothers Harriman & Co.’s holdings in Korro Bio were worth $95,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Quest Partners LLC boosted its position in shares of Korro Bio by 172.1% during the 3rd quarter. Quest Partners LLC now owns 1,777 shares of the company’s stock valued at $59,000 after purchasing an additional 1,124 shares in the last quarter. Lynx1 Capital Management LP acquired a new stake in Korro Bio during the second quarter valued at approximately $129,000. Rhumbline Advisers bought a new stake in Korro Bio during the second quarter worth approximately $279,000. Bank of New York Mellon Corp bought a new position in shares of Korro Bio in the second quarter valued at $649,000. Finally, Tri Locum Partners LP bought a new position in shares of Korro Bio in the second quarter valued at $2,419,000. 13.18% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CFO Vineet Agarwal sold 800 shares of Korro Bio stock in a transaction on Monday, November 11th. The stock was sold at an average price of $70.00, for a total transaction of $56,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.40% of the stock is currently owned by corporate insiders.

Korro Bio Stock Performance

Shares of NASDAQ KRRO opened at $54.99 on Friday. Korro Bio, Inc. has a one year low of $30.00 and a one year high of $98.00. The business has a 50-day moving average price of $52.13 and a two-hundred day moving average price of $46.54.

Korro Bio (NASDAQ:KRRO) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($2.26) EPS for the quarter, beating analysts’ consensus estimates of ($2.55) by $0.29. As a group, analysts anticipate that Korro Bio, Inc. will post -9.63 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on KRRO. HC Wainwright restated a “buy” rating and issued a $115.00 target price on shares of Korro Bio in a report on Friday, November 22nd. Raymond James assumed coverage on Korro Bio in a research note on Monday, October 21st. They issued a “strong-buy” rating and a $153.00 price target on the stock. Royal Bank of Canada upped their price objective on shares of Korro Bio from $95.00 to $105.00 and gave the company an “outperform” rating in a research note on Monday, October 21st. Finally, William Blair reissued an “outperform” rating on shares of Korro Bio in a research report on Wednesday, November 13th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $142.17.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).